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Background: In our previous study we found that
rhsIL-6R, along with recombinant human interleu-
kin-6, plays a regulatory role in the immune response
by modulating the tumour necrosis factor-a (TNF-a)
expression and its production by peripheral blood
mononuclearcells (PBMC). We also suggested that sIL-
6R with IL-6 secreted by human PMN (neutrophils)
influenced the TNF-a expression and its production
by autologous PBMC.
Aims: Since soluble gp130 (sgp130) is a natural
inhibitor for sIL-6R/interleukin-6 responses, in the
present study we estimated an effect of exogenous
recombinant human sgp130 and sgp130 secreted by
PMN on the TNF-a expression and its production by
PBMC.
Methods: Cells were isolated from whole blood of
healthy persons. The PMN were cultured in 96-well
plates for 1 h at 378C in a humidified incubator with
5% CO2. After the incubation, the culture supernatant
of PMN was removed and added to the PBMC. PBMC
were incubated for 1 h at 378C in the same conditions.
Cytoplasmic protein fractions of PMN and, for
comparative purpose of PBMC, were analysed for
presence of sgp130 by western blotting with the use
of monoclonal antibody capable of detecting this
protein. In the culture supernatants of PMN we
examined the concentrations of sgp130 by human
enzyme-linked immunosorbent assay. TNF-a was
measured at the protein levels as well as the mRNA
levels.
Results and conclusions: The present results re-
vealed that exogenous recombinant human sgp130
modulates the TNF-a expression and production by
PBMC. In contrast, we did not find any effect of
sgp130 secreted by PMN on the TNF-a expression and
its production by autologous PBMC.
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Introduction
Interleukin (IL)-6 belongs to a cytokine family that
includes IL-11, ciliary neurotrophic factor, oncostatin
M, leukemia inhibitory factor (LIF) and cardiotropin
1, granulocyte colony-stimulating factor, IL-12, IL-23,
and leptin.
13 This family is defined by the fact that
all its members use the transmembrane protein gp130
as a signal transducing receptor component. IL-6 and
IL-11, after binding to their specific a-receptors (IL-
6Ra), induce gp130 homodimerization, whereas LIF,
oncostatin M, ciliary neurotrophic factor and cardio-
tropin 1 signal via a heterodimer of gp130 and a
second signal transducing protein, the LIF recep-
tor.
2,4,5 Expression of the transmembrane gp130 was
found in almost all organs, including the heart,
kidney, spleen, liver, lung, placenta and brain.
6,7 In
contrast, cellular distribution of the cognate IL-6R is
limited and its expression is predominantly confined
to hepatocytes and the leukocyte subpopulation
(monocytes, neutrophils, T cells, and B cells).
6,7
gp130 activation leads to the activation of the Janus
family of tyrosine kinases (JAK-1, JAK-2 and TYK-2)
and subsequently to the activation of signal transdu-
cer proteins and proteins that activate transcription
(STAT proteins). Other signal transduction pathways
such as the mitogen-activated protein kinase pathway
and the phosphoinositol-3-kinase pathway are also
activated by gp130.
3,7,8
It was shown that membrane-bound receptors of
IL-6 exist in a soluble form: soluble IL-6Ra (sIL-6Ra)
and soluble gp130 (sgp130). sIL-6Ra binds IL-6 with
an affinity similar to that of the membrane-bound
receptor, and also prolongs its plasma half-life.
Moreover, the sIL-6R/IL-6 complex is capable of
activating cells via interaction with the membrane-
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355bound gp130. It is known that sIL-6R has a potential
to regulate both local and systemic IL-6-mediated
responses.
1,2,6,9
In our previous study we revealed that rhsIL-6R
with recombinant human interleukin-6 (rhIL-6) ap-
pear to play a regulatory role in the immune response
by modulating the tumour necrosis factor-a (TNF-a)
expression and its production by peripheral blood
mononuclear cells (PBMC).
10
sgp130 is the natural inhibitor of IL-6 responses
that is dependent on sIL-6R. sgp130, by interacting
with the IL-6/sIL-6R complex (but not with IL-6
alone), specifically inhibits IL-6 responses mediated
by the sIL-6R trans signalling pathway, whereas IL-6
responses through the membrane-bound IL-6R re-
mained unaffected.
4,6
In the present study we estimated a role of
recombinant human sgp130 (rhsgp130) and sgp130
secreted by PMN in the TNF-a expression and
production by autologous PBMC. Examination of
the biological function of sgp130 may provide new
information about a potential activity of this receptor
in the immune response mediated by IL-6 and TNF-a.
Materials and methods
Cells were isolated from heparinized (10 U/ml)
whole blood of 15 healthy persons by Gradisol G
gradient (1.115 g/ml). The purity of isolated PMN and
PBMC was determined by May/Grunewald/Giemsa
staining: PBMC contained 95% lymphocytes and
polymorphonuclear cells contained 94% PMN. PMN
were suspended in the culture medium (RPMI-1640,
autologous serum, penicillin and streptomycin) to
provide 5/10
6 cells/cm
3. The PMN were cultured in
96-well plates (Falcon, Franklin Lakes, NY, USA) for 1
ha t3 7 8C in a humidified incubator with 5% CO2
(Nuaire
TM; Nu Aire, Inc., Minnesota, USA). After
incubation, the culture supernatant of PMN was
removed and added to PBMC (5/10
6 cells/cm
3).
The viability of PMN was  /92% as determined by
trypan blue exclusion. PBMC were incubated for 1 h
at 378C in the same conditions. PBMC with the
culture supernatants of PMN and monoclonal anti-
body (mAb) anti-sgp130 (20 ng/ml) (R&D Systems,
Minneapolis, MN, USA), and anti-IL-6 (20 ng/ml)
(Biorsource, Nivelles, Belgium) were the negative
control, whereas PBMC with rhsgp130 (1 mg/ml)
(R&D Systems) and rhIL-6 (50 ng/ml) (R&D Systems)
were the positive control.
Cytoplasmic protein fractions of PMN and, for
comparative purposes, of PBMC were analysed for
the presence of sgp130 by western blotting using
mAb capable of detecting this protein anti-sgp130
(R&D Systems) (Jackson ImmunoResearch Inc., from
BIOKOM, Warsaw, Poland). Cells were lysed directly
by sonication and cytoplasmic proteins were electro-
phoresed on sodium dodecyl sulphate-polyacryla-
mide gel electrophoresis. The resolved proteins were
transferred onto nitrocellulose and incubated with
the primary mAb anti-sgp130. The membranes were
incubated at room temperature with alkaline phos-
phatase anti-mouse immunoglobulin G. Immunor-
eactive protein bans were visualized by the AP
Conjugate Substrate Kit.
In the culture supernatants of PMN we examined
the concentrations of sgp130 by human enzyme-
linked immunosorbent assay (ELISA) (Biosource and
R&D Systems).
TNF-a was measured at both the protein and
mRNA levels. Protein levels were determined by a
human TNF-a ELISA.
To examine TNF-a mRNA expression we isolated
mRNA from PBMC after culture, using TRIZOL
Reagent (Gibco, Paisley, UK) according to the
manufacturer’s instruction. The quantity of mRNA
TNF-a was determined by Quantikine mRNA assay /
Human TNF-a (R&D Systems).
Results
sgp130 protein expression in human PMN and
PBMC detected by western blot
We used a specific mAb directed against intracellular
forms of sgp130 for western blot in PMN and, for
comparative purpose, in PBMC. As shown in Fig. 1
the antibody in human unstimulated and lipopoly-
sacccharide (LPS)-stimulated PMN and PBMC identi-
fied bands of /110 kDa from each donor.
Western blot analysis showed that the samples of
unstimulated PMN and PBMC contained a 110 kDa
protein, which was stained by an anti-sgp130 mono-
clonal antibody. The LPS-stimulated PMN and PBMC
expressed a slightly increased sgp130 protein in
comparison with the unstimulated cell lines.
FIG. 1. Western blot analysis of sgp130 protein expression in
human PMN and PBMC. We showed detection of sgp130
protein from human unstimulated PMN (line A) and LPS-
stimulated PMN (line B), unstimulated PBMC (line C), and
unstimulated PBMC (line D). Whole cell lysates were
obtained from fresh PMN of healthy donors. One hundred
micrograms of total proteins from PMN was loaded onto
10% sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis and transferred to a nitrocellulose ﬁlter. The ﬁlter
was incubated with 1:1000 dilution of the respective anti-
body. Sizes of protein standards are given in kilodaltons.
One representative western blot of few independent experi-
ments is shown.
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supernatants of PMN detected by ELISA
In the culture supernatants of unstimulated PMN we
observed a significant amount of sgp130 (mean9 /
standard deviation, 27.69 /14.2 ng/ml). LPS stimula-
tion led to an increase in the sgp130 production by
PMN (mean9 /standard deviation, 41.89 /22.3 ng/ml)
in comparison with the unstimulated cells.
TNF-a mRNA in PBMC
In the culture supernatants of PBMC that were
cultured in the presence of supernatants of unstimu-
lated PMN, concentrations of TNF-a mRNA were
lower than those in the supernatants of PBMC
cultured without PMN supernatants (Fig. 2A). The
supernatants of LPS-stimulated PMN led to a slightly
enhanced TNF-a expression in PBMC. TNF-a expres-
sion in the culture supernatants of PBMC cultured
with rhsgp130 and rhIL-6 was higher than in PBMC
cultured with unstimulated PMN.
Anti-sgp130 monoclonal antibody with rhIL-6 was
used to confirm whether actions of PMN supernatant
has been generated by this protein. The presence of
anti-sgp130 antibody in the culture of PBMC with
PMN supernatants induced lower levels of TNF-a
expression in comparison with PBMC cultured with-
out PMN.
TNF-a concentrations in the culture
supernatants detected by ELISA
Concentrations of TNF-a in the culture supernatants
of PBMC culture in the presence of supernatants of
unstimulated PMN were lower than those in the
supernatants of PBMC cultured without PMN super-
natants (Fig. 2B). In the presence of LPS-stimulated
PMN supernatants we found non-significantly higher
amounts of TNF-a in the supernatants of PBMC in
FIG. 2. TNF-a expression and its production by unstimulated and stimulated PBMC: (A) TNF-a mRNA expression (amol/cm
3);
(B) TNF-a concentration in the culture supernatant of PBMC (pg/ml). * Statistical difference with PBMC alone (pB/0.05).
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PMN. PBMC cultured with rhsgp130 and rhIL-6
secreted higher concentrations of TNF-a than PBMC
alone. The presence of anti-sgp130 and rhIL-6
induced a lower level of TNF-a than in the culture
of PBMC alone.
Discussion
Soluble cytokine receptors through the control of
cytokine bioactivity play a significant role in the
immune response. There are different data referring
to the biological activity of soluble receptors alone or
complexed with respective ligand.
9,11 It was well
established that the soluble IL-6 receptors (sIL-6Ra
and sgp130) have opposite biologic effects. However,
sgp130 antagonistic activity is markedly enhanced in
the presence of sIL-6Ra.
1 It has recently been shown
that sIL-6Ra and sgp130 could be effective stimulators
of the cell activity.
9,12,13 For instance, Modur et al.
demonstrated that PMN exposed to fMLP shed IL-6R
in sufficient quantities to activate the inflammatory
response of endothelial cells.
9 sgp130 has been
shown to inhibit sIL-6R-mediated proliferation of
Kaposi sarcoma cells, STAT activation and the ex-
pression of a1-antichymotrypsin.
6 Aukrust et al.
demonstrated that sgp130 correlates with variables
reflecting a deranged haemodynamic status. This
indicate the involvement of sgp130 in the pathophy-
siology of cardiovascular disease.
14
The present study indicate that exogenous
rhsgp130 has the ability to enhance the TNF-a
expression and its production by human PBMC. In
contrast, we did not find any significant effect of
sgp130 released by human PMN on the TNF-a
expression and its production by autologous PBMC.
One possible explanation of this situation may be the
presence of other mediators in the culture super-
natants of PMN as well as of PBMC. PMN have the
ability to synthesize pro-inflammatory and anti-in-
flammatory cytokines that co-stimulate each other’s
release and activity. In our previous study we found
that IL-6 together with sIL-6R secreted by PMN
inhibits the TNF-a expression and production by
PBMC.
10 Moreover, neutrophils may affect the IL-6
function through the release proteases playing a
crucial role in regulation of the biological potency
of this cytokine at sites of inflammation.
15 Among the
known anti-inflammatory mediators secreted by
PMN, IL-10 was shown to inhibit the production of
TNF-a.
16 Furthermore, cytokines produced by PBMC,
such as IL-4, IL-6 and IL-10, in an autocrine way may
influence the TNF-a expression.
Although, we did not observe any significant effect
of sgp130 on TNF-a expression in PBMC, the secre-
tion of a relatively large amount of sgp130 by PMN
might directly affect the other biological function of
IL-6. It is known that the lack of sgp130 may lead to
overstimulation of reactions mediated by the IL-6/sIL-
6R complex. Jones and Rose-John showed that
sgp130 can modulate the leukocyte recruitment in a
murine model of acute inflammation and can sup-
press the clinical indices of experimental colitis.
6
Thus, sgp130 as natural inhibitor of the IL-6/sIL-6R
complex can be useful in blocking the sIL-6R
responses in different diseases.
4
In estimation of the biological function of sgp130
released by neutrophils, as well as by other cells, the
presence of three isoforms of this protein should be
considered. Soluble sgp130 is generated through
either proteolytic shedding or as a product of
differential mRNA splicing. The 50, 90 and 110 kDa
forms of sgp130 are secreted by shedding of mem-
brane-bound gp130. A spliced variant of sgp130
containing an additional 85 base pair insertion was
also found. Recently, a third isoform of sgp130 (the
55 kDa molecule) was identified as the autoantigen in
rheumatoid arthritis.
6 It is possible that these iso-
forms, like isoforms of sIL-6Ra, may have various
biological effects. Additionally, recent data indicate
that an inhibitory action of sgp130 is not restricted to
suppressing sIL-6R signalling and may also block LIF-
mediated and oncostatin M-mediated events.
4 Thus,
sgp130 may influence a wider range of reactions in
the immune response than recognized to date.
Summarizing, the relationship between both solu-
ble IL-6 receptors should be considered in the
estimation of reactions mediated by the IL-6 family
and TNF-a. Neutrophils, abundant cells of an early
phase of inflammation, through the simultaneous
release of sIL-6R and sgp130 appear to play a
significant role in this response. However, further
examinations involving a wider range cytokines are
required to explain the lack of effect of sgp130
secreted by PMN on TNF-a expression in autologous
PBMC.
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